Published in TB and Outbreaks Week, April 19th, 2005
According to a recently published report from the United States, "A stable, polymerized hemoglobin product has been formulated that overcomes the three traditional hurdles of hemoglobin-based blood substitutes: nephrotoxicity, osmotic diuresis, and bloodborne pathogens."
G. Allison and colleagues at Highland General Hospital in Oakland present "a case of a patient with persistent colonic bleeding and a hemoglobin of 2.9 g/100 mL."
"Since her religious faith prevented her from accepting blood products," the authors concluded, "we offered a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week